Year End Update on Business Activities and Outlook
BRAIN+ A/S (BRAINP)
Wednesday, December 29, 2021, 9:00 CET
Investor update
Partnership with Rox Health and expected first product launch two years ahead of plan: This past week, we announced a partnership with Rox Health (www.roxhealth.com), a daughter company of Roche (www.roche.com). The commitment of Rox gives us access to valuable market insights, expert advisory resources and user channels to support commercial launch of our first CST (Cognitive Stimulation Therapy) product to treat people with dementia in the biggest and probably most attractive European market: Germany. With the agreement with Rox, we now expect to launch our CST product in Germany already in 2023, which is about two years ahead of plan.
Strong starting point for 2022 with validation from major player: We went public less than 3 months ago, yet we are already in a stronger than expected position with the Rox Health partnership. A position that opens us to faster commercial traction with a first regulated product, and additional financial resources from the deal to achieve this. It is also important that our approach has been validated by a major player in the industry. We now have buy-in from the industry needed to accelerate towards our commercial goal: to become a global leader in software-as-medicine to provide new therapeutic options for patients with Alzheimer’s and dementia.
Further strengthening of the team: With the proceeds from our IPO we are working on and have already succeeded in further strengthening our organization to ensure the necessary competences to deliver on our milestones, including clinical advancement of our technologies and products.
New, strong regulatory expertise: As a tangible step in building a complete team, we are pleased to welcome Shilpa Ashok Razdan as our New Senior Regulatory Manager. Shilpa brings unique regulatory expertise in the area of software-as-a-medical device (software for treatments) (https://www.linkedin.com/in/razdanshilpa/). She will manage the regulatory work of Brain+, including driving both internal and external regulatory processes for an optimal route to market for our products. Shilpa will have as a core task to build a strong collaboration with the Rox Health regulatory team to get our first CST product approved for market launch in German in 2023.
Co-founder moves into strategic advisory role: Now well through the IPO and well underway to build a streamlined organization focused on the development of clinically validated ‘software-as-medicine’ products, it has been agreed that our Chief Product Officer and co-founder, Ulrik Ditlev Eriksen, will move out of his operational role and into a free, strategic advisory role for the CEO and support the company in relation to strategic projects. The product management responsibility going forward will be placed in the company’s commercial function.
Kim Baden Kristensen, CEO and co-founder: “I am very pleased with the progress we have made since the IPO. We have our first big pharma collaboration in place and based on this, now foresee the launch of our first product to help stimulate cognition in people with dementia in Germany two years ahead of plan. Further, we have made important additions to our highly competent team, and I am truly thankful for the dedication all employees are showing to execute on our goal: restore independence and quality of life of Alzheimer’s and other dementia patients by treating and detecting the cognitive decline associated with their disease. I wish also to thank all our investors for their support on this important journey”.
Contact Information
CEO, Kim Baden-Kristensen + 45 31393319, E-mail: kim@brain-plus.com, Brain+ A/S, Købmagergade 53, 3.
Certified Advisor: Keswick Global AG, + 43 1 740 408045 , E-mail: info@keswickglobal.com
About BRAIN+ [BRAINP]
The mission of Brain+ is to restore patients’ independence and quality of life by treating and detecting cognitive decline in Alzheimer’s disease and dementia through digital means. Brain+ has developed a set of Digital Medicine technologies, which enable the Company to create a unique and differentiated product offering. These technologies, combined with a strong clinical pipeline, Brain+ is in a strong position to grow towards a market leader position in the major Digital Medicine space. For more information www.brain-plus.com/investor
